Adding to recent NASH failures, Boehringer drops BI 1467335 development
In another disappointment for the treatment of fatty liver disease, Germany’s family-owned Boehringer Ingelheim today announced the discontinuation of the development of BI 1467335 for the treatment of NASH (non-alcoholic steatohepatitis).
BI 1467335 was acquired from Australia’s Pharmaxis (ASX: PXS) in 2015. This involved an upfront payment of 27.5 million euros ($30.6million a current exchange rates) and a total potential deal value of over A$750 million ($555 million). As part of its ambitions in the NASH arena, Boehringer also signed collaborations with Yuhan, Dicerna and Mina.
Pharmaxis shares closed trading today down more than 40% at A$0.16, having fallen as low as A$0.15.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze